For myself its all about risk versus reward.....Right now we have a MC of around $225 million CDN give or take depending on fluctuations in the PPS.  I have my own guesses about where I think the MC could go with a positive futility analysis, and another figure base on a successful BETonMACE trial.  Needless to say those MC guesses are substantially higher than the current MC.  With a thumbs up on the futility analysis I can envision our MC at least doubling and possibly even tripling that's my opinion.  

Why double for a positive futility analysis?

Because one of the risks here is that of failure, that Apabetalone could ultimately fail to meet its primary end point of signficant RRR in Diabetes patients.  While a positive futility analysis would not totally eliminate that risk, it my opinion it would substantially lessen that risk, which I believe would be reflected in the market's valuation of RVX.  

And then, assuming we get that thumbs up and ultimately succeed in meeting the desired end points....then I could see the MC going to at least $1 billion in USD, and I think that is being incredibly conservative...by a factor of at least 100% if not more.

That's why I'm not getting my shorts all in a knot over the prospects of a dilutive secondary or PP.....one of the factors that I believe is weighing the PPS down is the risk that the company won't be able to secure the needed financing.  Eliminate that risk by raising enough $$$ to get to the finish line....then I can see it being, at worst, a wash....depending on the details of course.  

If our MC was already up around 800 or 900 million however.....then I wouldn't see as much upside potential, and I'd see a lot more down side risk.  But the way things are now I might just be adding again, I already have added a few thousand last week and this week.